NMRA Stock Forecast & Price Target

Neumora Therapeutics is viewed favorably because its post-navacaprant strategy is now more focused on higher-probability neuroscience assets, notably NMRA-898, NMRA-511, and NMRA-215, each with multiple catalysts over the next 12-18 months. The company’s balance sheet and restructuring actions also support the thesis, with about 35% workforce reduction expected to save roughly $10 million annually, partially offset by about $2 million of one-time costs, while cash is expected to fund operations into 3Q27. Despite the KOASTAL setback, the pipeline remains differentiated and potentially first- or best-in-class, and the investment case is anchored by a present value of 5x the 2035 risk-adjusted revenue estimate of $977 million.

Neumora Therapeutics is facing a materially weakened investment case after discontinuing navacaprant development when KOASTAL-2/3 failed to meet the primary MADRS endpoint or the key SHAPS measure, showing no meaningful efficacy separation versus placebo. The readouts were essentially flat, with KOASTAL-2 at -12.2 versus -12.0 and KOASTAL-3 showing similar results, undermining confidence in the KORA mechanism and the thesis that greater selectivity would differentiate the asset. Management’s 35% workforce reduction and expected $10M in annualized savings help reduce burn, but the loss of a lead program leaves a narrower, earlier-stage pipeline across seven programs and a less compelling fundamental profile.